Please assess the completion status of the following clinical trial:

Trial Title: Tumor Gene Expression in Women With Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has intraabdominal disease either proven or strongly suspected to be ovarian or primary peritoneal cancer, and will be undergoing surgical debulking.~* Subject is not allergic to dexamethasone, and there is no obvious medical contraindication to dexamethasone.~* Subjects with diabetes requiring drug therapy are excluded.~* Subject is not currently receiving glucocorticoid therapy~* Nasal steroids (e.g. Flonase) are permitted~* Subject understands that this protocol does not have therapeutic intent~* Preoperative serum albumin at least 3.0 mg/dL~* Negative serum or urine pregnancy test in women of childbearing potential~* Signed informed consent~Exclusion Criteria:~* Males do not get ovarian cancer and therefore will not be included in this trial.~* Patients of all ethnic backgrounds are eligible and will be encouraged to enroll. However we do not expect differences based on ethnicity, and this small study will not therefore be powered to make conclusions about ethnic differences in induction of GR-regulated genes with dexamethasone.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): 20 mg of dexamethasone
- Placebo [Saline] (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).